tailieunhanh - Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis

Zalypsis® is a marine compound in phase II clinical trials for multiple myeloma, cervical and endometrial cancer, and Ewing’s sarcoma. However, the determinants of the response to Zalypsis are not well known. The identification of biomarkers for Zalypsis activity would also contribute to broaden the spectrum of tumors by selecting those patients more likely to respond to this therapy. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN